Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Artiva Biotherapeutics, Inc.ARTV · Entity 5404 | Director | September 10, 2026 | September 14, 2026 |
| Cue Biopharma, Inc.CUE · Entity 6301 | CHIEF DEVELOPMENT OFFICER | April 09, 2026 | April 10, 2026 |
| Shattuck Labs, Inc.STTK · Entity 5224 | Director | May 29, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Artiva Biotherapeutics, Inc.
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2036-09-09 | Direct | 16,250 |
Reported balance
After 2026-09-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-10 · Grant · Acquired 16,250 · Balance 16,250 F1: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.
Cue Biopharma, Inc.
Report date April 09, 2026 · Filed April 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.29 · Expires 2036-04-08 | Direct | 100,000 |
Reported balance
After 2026-04-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-09 · Grant · Acquired 100,000 · Balance 100,000 F1: This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter.
Shattuck Labs, Inc.
Report date May 29, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.95 · Expires 2036-05-29 | Direct | 81,000 |
Reported balance
After 2026-05-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 81,000 · Balance 81,000 F1: This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 14, 2026 20:03 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantDirector Stock Option (Right to Buy) · Derivative | 16,250 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0001193125-26-390527 · ownership.xml · derivative · entry 1 Baker Daniel G. · CIK 0002046802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,250 Underlying: Common Stock · 16,250 shares Expires 2036-09-09 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 21:55 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantDirector Stock Option (Right to Buy) · Derivative | 13,750 | $0.00 Strike: $10.88 | $0.00 |
DisclosureSEC source: 0001193125-26-385412 · ownership.xml · derivative · entry 1 Baker Daniel G. · CIK 0002046802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2036-09-07 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:00 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 81,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001193125-26-254127 · ownership.xml · derivative · entry 1 Baker Daniel G. · CIK 0002046802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 81,000 shares Expires 2036-05-29 F1 · derivative.exercise_date: This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001193125-26-151200 · ownership.xml · derivative · entry 1 Baker Daniel G. · CIK 0002046802 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-04-08 F1 · derivative.exercise_date: This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter. Read SEC document |
| September 29, 2025 Filed Nov 25, 2025 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001193125-25-296985 · ownership.xml · derivative · entry 1 Baker Daniel G. · CIK 0002046802 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-09-28 F1 · derivative.exercise_date: This stock option becomes fully exercisable on the first anniversary of the grant date. Read SEC document |
| August 28, 2025 Filed Sep 2, 2025 10:35 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 66,300 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001193125-25-193327 · ownership.xml · derivative · entry 1 Baker Daniel G. · CIK 0002046802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,300 Underlying: Common Stock · 66,300 shares Expires 2035-08-28 F1 · derivative.exercise_date: This option represents the right to purchase a total of 66,300 shares of the Issuer's common stock, and vests in three equal annual installments on each of the first three anniversaries of August 28, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:30 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantDirector Stock Option (Right to Buy) · Derivative | 13,750 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001415889-25-018278 · form4-06262025_040608.xml · derivative · entry 1 Baker Daniel G. · CIK 0002046802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2035-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0000950170-25-044346 · ownership.xml · derivative · entry 1 Baker Daniel G. · CIK 0002046802 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-03-20 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 21:33 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantDirector Stock Option (Right to Buy) · Derivative | 27,500 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0001415889-25-002273 · form4-01292025_090134.xml · derivative · entry 1 Baker Daniel G. · CIK 0002046802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2035-01-27 F1 · derivative.exercise_date: One-third of the shares vested following the grant date, with the remaining shares vesting monthly over an additional two years following January 28, 2025, Read SEC document |
| November 25, 2024 Filed Nov 29, 2024 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0000950170-24-131890 · ownership.xml · derivative · entry 1 Baker Daniel G. · CIK 0002046802 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-11-24 F1 · shares: Represents an inducement stock option granted on November 25, 2024. F2 · derivative.exercise_date: This stock option will become exercisable over two years in equal, semi-annual installments beginning on May 25, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.